T ranscatheter aortic valve replacement (TAVR) has revolutionized the management of severe aortic stenosis. In several randomized trials studying extreme-, high-, and intermediate-risk patients, TAVR has been shown to be superior to medical treatment and noninferior to surgical aortic valve replacement. [1] [2] [3] [4] The family of SOURCE (SAPIEN Aortic Bioprosthesis European Outcome) and PARTNER (Placement of Aortic Transcatheter Valve) trials have evaluated the use of the balloonexpandable SAPIEN, SAPIEN XT, and SAPIEN 3 transcatheter heart valves (Edwards Lifesciences, Irvine, CA). The SAPIEN 3 valve is the latest generation of balloon-expandable transcatheter heart valves, which contains modifications that improve on the earlier valves. These modifications included a mechanism to reduce paravalvular regurgitation (PVR), the need for a smaller expandable femoral sheath size that accommodates ≈90% transfemoral TAVR use, and a mechanism to permit fine-tuning of the transcatheter heart valve during positioning. These iterations were designed to decrease complication rates, to facilitate deployment, and to expand the indications and application of TAVR to a wider population of patients. With this in mind, it will be paramount to analyze the efficacy and safety of the SAPIEN 3 transcatheter heart valve as we move toward a younger and lower-risk population.
In this issue of Circulation, Wendler and colleagues 5 report the 30-day outcomes of the SOURCE 3 registry. This is the largest real-world observation of the safety and performance of the SAPIEN 3 valve in 1947 patients from 80 centers in 10 European countries enrolled between July 2014 and October 2015. They report a high implantation success rate (98.3%) and low rates of conversion to surgery (0.6%) or use of cardiopulmonary bypass (0.7%). At 30 days, they note low rates of adverse events (all-cause mortality, 2.2%; cardiovascular mortality, 1.1%; stroke, 1.4%; major vascular complications, 4.1%; and moderate or greater PVR rate, 3.1%). Moreover, they noted excellent postimplantation hemodynamics. However, there remains a higher post-TAVR permanent pacemaker (PPM) implantation rate at 12%. Their results are comparable to those of PARTNER registry patients of equivalent risk (allcause mortality, 1.1%; cardiovascular mortality, 0.9%; stroke, 2.7%; slightly higher major vascular complications, 12.2%; moderate or greater PVR rate, 3.4%, and new PPM insertion, 10.1%). 6 These excellent outcomes are quite encouraging compared with previous versions of the registry, as highlighted by the authors. 7 Compared with SOURCE XT, the smaller sheath size in SOURCE 3 allowed an increase in transfemoral TAVR from 62.7% to 87.1%. Similarly, the use of SAPIEN 3 compared with SAPIEN XT showed a decrease in all-cause mortality (from 6.3% to 2.2%) and cardiovascular mortality (from 3.0% to 1.1%). Stroke rates were reduced from 3.6% to 1.4%, major vascular complications from 6.5% to 4.1%, and moderate or greater PVR from 5.5% to 3.0%. These improvements are multifactorial. On the one hand, there are technology-independent Early Results of the SOURCE 3 Registry A Source of Encouragement With Some Caveats factors such as a lower-risk population evident by decreased mean logistic EuroSCORE, increased experience in patient selection, valve sizing with computed tomography, and valve delivery and deployment. On the other hand, technology-dependent factors include a reduction in diameter of the introducer devices and nose cone to facilitate transfemoral access and lower the crossing profile; greater active flexion to keep the device off the aortic arch greater curvature, which allows more coaxial valve crossing; and a sealing skirt mounted around the stent to reduce PVR. Although this is an extensive realworld experience, without a comparator arm in a randomized setting, it is difficult to attribute all the improvements solely to amelioration of the technology. However, the aforementioned changes in the valve and its accessories make mechanistic sense in how they may contribute to at least some of the observed improvements in outcomes.
The SOURCE 3 results compared favorably with the PARTNER 2A trial results 4 and are likely driven by a combination of experience and an improved valve design (SA-PIEN 3 versus SAPIEN XT) but may also be due to the patients in PARTNER 2A being generally sicker with more extensive comorbidity burden. At 30 days, SOURCE 3 versus PARTNER 2A patients had lower rates of all-cause mortality (2.2% versus 3.9%), cardiovascular mortality (1.1% versus 3.3%), stroke (1.4% versus 3.2%), major vascular complications (4.1% versus 7.9%), and moderate or greater PVR (3.1% versus 3.7%). However, the PPM insertion rates are higher in the SOURCE 3 registry (12% versus 8.5%). Although SOURCE 3 and PARTNER 2A patients had comparable baseline demographics (age, 82 years in both; male sex, 51% versus 54%), PARTNER 2A patients had a higher proportion of comorbidities and were generally sicker (prior coronary artery bypass surgery, 24% versus 9.4%; diabetes mellitus, 38% versus 29%; peripheral vascular disease, 28% versus 12%; chronic obstructive pulmonary disease, 32% versus 15%). Once again, the latter point may have contributed to the slightly better results in the SOURCE 3 registry.
One area of notice is the increased rates of PPM insertion, which doubled from 6% to 12% since the SOURCE XT registry. Recently, in the PARTNER 2 analysis of 1077 patients with SAPIEN 3, the 30-day PPM rate was 10.2%. 6, 8 The rates of pacemaker implantation will need to be carefully monitored in TAVR technology as we consider younger and lower-risk patients, and the longterm consequences of a PPM are likely more significant in this younger population. The increased rate of PPM insertion is likely due to the longer stent frame possibly resulting in more ventricular implantations and increased risk of injury to the conduction system. Although we have altered our implantation depth currently to 80% aortic and 20% ventricular, this may not have been the case early in this series or the PARTNER S3 trials. It would have been interesting for the authors to evaluate the degree of oversizing, depth of implantation, and baseline conduction abnormalities to determine the exact pathogenesis and to develop potential strategies to decrease PPM insertion rates. If TAVR is to become a viable alternative to surgical aortic valve replacement in lower-risk patients, the PPM insertion rate should be noninferior to surgery. Whether this will be driven by improvements in the engineering of the valve, implantation strategies, or both is still to be determined. However, there is a recent encouraging European report of a 4.0% PPM insertion rate with the SAPIEN 3 valve in intermediate-risk patients, demonstrating that the goal of <5% PPM rate is indeed attainable and should be achievable. 9 The current European report and the reports from the PARTNER 2 trial have shown a significant improvement of PVR with the SAPIEN 3 valve compared with prior versions of balloon-expandable valve. It is encouraging to see the decreasing rates of PVR after TAVR as a result of improved preoperative imaging, increased operator experience, and device improvements in technology (eg, the addition of ventricular skirt to the SAPIEN 3). However, similar to the PPM implantation, PVR remains an important consideration when TAVR is compared with surgery in younger patients. Although detrimental consequences of moderate and severe PVR after TAVR 6 and surgery remain, the goal for these younger patients should be a <1% moderate to severe PVR.
What is quite surprising from the results is the long intensive care unit and hospital lengths of stay (median, 2 and 7 days, respectively). These numbers remain high in the transfemoral group of patients. Despite moving toward conscious sedation (52% in all patients and 60% in transfemoral patients) and improved outcomes in a lower-risk population, these lengths of stay are high and could be improved. 6 We congratulate the authors for these excellent and encouraging TAVR results and look forward to the outcomes with this technology in younger patients, albeit with longer-term follow-up. The results of the 2 ongoing US randomized trials in low-risk patients with 10-year follow-up will be critical as we determine whether TAVR will become the standard of care for aortic stenosis.
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